InsiderTrades

Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC

Accepted 2022-11-16 00:00:00 ET · period of report 2022-11-14 · accession 0001127602-22-025761 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-11-16 2022-11-14 BCRX Babu Yarlagadda S Chief Discovery Off M - OptEx $1.42 +100.0K 330.1K +43% +$142.0K
D 2022-11-16 2022-11-14 BCRX Babu Yarlagadda S Chief Discovery Off S - Sale+OE $13.88 -31.5K 298.5K -10% -$437.4K
DM 2022-11-16 2022-11-14 BCRX Babu Yarlagadda S Chief Discovery Off M - OptEx $0.00 -100.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-11-14 M A 50,000 $1.42 280,056 D — —
2 Common Common Stock 2022-11-14 S D 31,515 $13.88 298,541 D — — (F1) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
3 Common Common Stock 2022-11-14 M A 50,000 $1.42 330,056 D — —
4 Derivative Emp. Stock Option (Right to Buy) 2022-11-14 M D 50,000 $0.00 0 D $1.42 · 2014-01-01 to 2023-01-01 50,000 Common Stock (F2) Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date.
5 Derivative Emp. Stock Option (Right to Buy) 2022-11-14 M D 50,000 $0.00 0 D $1.42 · 2014-01-01 to 2023-01-01 50,000 Common Stock (F3) Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date.